Dr Reddy’s Laboratories Ltd shares rose on Tuesday after the company said it had received the U.S. drug regulator’s approval for selling its generic version of an anti-cancer drug by Celgene Corp’s.
Vidaza, the anti-cancer drug, generated sales of $378.5 million in the United States in the 12 months through July, according to IMS Health
Dr. Reddy’s, whose shares ended 3.6 percent higher, said in a statement it plans to launch the drug in the United States shortly.
“It’s a decent positive for DRL as it is definitely a limited competition drug, but whether the company has a first-to-file would get clarified in the next few days when other players get approval,” said Ranjit Kapadia, an analyst tracking the sector at Centrum Broking.
The first company to file a successful application with the U.S. Food and Drug Administration to sell a generic version of a drug coming off patent gets a six-month exclusivity period in the United States.